Cytokinetics, Incorporated (CYTK)

Market Cap	6.29B
Revenue (ttm)	3.75M
Net Income (ttm)	-530.60M
Shares Out	114.66M
EPS (ttm)	-5.40
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,140,274
Open	54.97
Previous Close	54.70
Day's Range	53.39 - 54.97
52-Week Range	25.98 - 110.25
Beta	0.75
Analysts	Buy
Price Target	78.25 (+42.69%)
Earnings Date	Aug 1, 2024

About CYTK

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that i...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 29, 2004
• Employees: 423
• Stock Exchange: NASDAQ
• Ticker Symbol: CYTK

Financial Performance

In 2023, Cytokinetics's revenue was $7.53 million, a decrease of -92.04% compared to the previous year's $94.59 million. Losses were -$526.24 million, 35.3% more than in 2022.

Analyst Forecast

According to 16 analysts, the average rating for CYTK stock is "Buy." The 12-month stock price forecast is $78.25, which is an increase of 42.69% from the latest price.

Price Target

$78.25

(42.69% upside)

Analyst Consensus: Buy